For type 2 diabetes mellitus. ANDA 77078, held by Zydus Lifesciences. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 77078 (Metformin Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Apr 21, 2005, with 5 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 15, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 15, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 31, 2008 | Supplement 3Labeling | Approved | None posted |
| Jan 28, 2008 | Supplement 2Labeling | Approved | None posted |
| Apr 21, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters